Marcelo Marotti
About
Marcelo Marotti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Marcelo Marotti has authored 29 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Marcelo Marotti's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (5 papers). Marcelo Marotti is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (5 papers). Marcelo Marotti collaborates with scholars based in United Kingdom, United States and Japan. Marcelo Marotti's co-authors include Yi‐Long Wu, Helen Mann, Tony Mok, Vassiliki A. Papadimitrakopoulou, Willemijn S.M.E. Theelen, Serban Ghiorghiu, Alison Templeton, Suresh S. Ramalingam, Yong He and Hiroaki Akamatsu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Marcelo Marotti
29 papers receiving 3.2k citations
Hit Papers
Peers
Marcelo Marotti
Jolanda Paolini United States
Willemijn S.M.E. Theelen Netherlands
Zofia Piotrowska United States
Hiroaki Akamatsu Japan
David A. Ramies United States
Venice Archer United Kingdom
Kathryn H. Brown United Kingdom
Viola W. Zhu United States
Bogdana Balas Switzerland
Russell F. DeVore United States
Citations per year, relative to Marcelo Marotti Marcelo Marotti (= 1×)
peers
Jolanda Paolini
Countries citing papers authored by Marcelo Marotti
Since
Specialization
Citations
This map shows the geographic impact of Marcelo Marotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcelo Marotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcelo Marotti more than expected).
Fields of papers citing papers by Marcelo Marotti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marcelo Marotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcelo Marotti. The network helps show where Marcelo Marotti may publish in the future.
Co-authorship network of co-authors of Marcelo Marotti
This figure shows the co-authorship network connecting the top 25 collaborators of Marcelo Marotti. A scholar is included among the top collaborators of Marcelo Marotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcelo Marotti. Marcelo Marotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Concannon, Kyle, Bonnie S. Glisson, Robert C. Doebele, et al.. (2024). A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 25(7). 601–611.
2.
Heymach, John V., Nuria Kotecki, Hans Prenen, et al.. (2023). 665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation. Annals of Oncology. 34. S468–S468.
3.
Waizenegger, Irene C., Hengyu Lu, Claus Thamer, et al.. (2022). Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation. Cancer Research. 82(12_Supplement). 2667–2667.
4.
Hofmann, Marco H., Hengyu Lu, Daniel Gerlach, et al.. (2021). Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.. Cancer Research. 81(13_Supplement). CT210–CT210.
5.
Vishwanathan, Karthick, Bhumsuk Keam, Nicolas Penel, et al.. (2020). A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacology Research & Perspectives. 8(4). e00613–e00613.
6.
Creelan, Ben, Tammie C. Yeh, Sang-We Kim, et al.. (2020). A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. British Journal of Cancer. 124(2). 383–390.
7.
Tsuboi, Masahiro, Roy S. Herbst, Thomas John, et al.. (2019). Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection. Annals of Oncology. 30. v589–v589.
8.
Wu, Yi‐Long, Roy S. Herbst, Helen Mann, et al.. (2018). ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer. 19(4). e533–e536.
9.
Mok, Tony, Yi‐Long Wu, M. Ahn, et al.. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. QUT ePrints (Queensland University of Technology).
10.
Papadimitrakopoulou, Vassiliki A., Yi‐Long Wu, Myung‐Ju Ahn, et al.. (2017). PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3). Journal of Thoracic Oncology. 12(1). S5–S6.
11.
Wu, Yi‐Long, Suzanne Jenkins, Suresh S. Ramalingam, et al.. (2017). MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis. Journal of Thoracic Oncology. 12(1). S386–S386.
12.
Mok, Tony, Yi‐Long Wu, Myung‐Ju Ahn, et al.. (2016). Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. New England Journal of Medicine. 376(7). 629–640.
13.
Judson, Ian, Michelle Scurr, Kate Gardner, et al.. (2014). Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma. Clinical Cancer Research. 20(13). 3603–3612.
14.
Banerji, Udai, Malcolm Ranson, Jan H.M. Schellens, et al.. (2013). Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .. Cancer Research. 73(8_Supplement). LB–66.
15.
Herpen, Carla M.L. van, Ulrik Lassen, Ingrid M.E. Desar, et al.. (2012). Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anti-Cancer Drugs. 24(2). 204–211.
16.
Trarbach, Tanja, Beate Schultheis, Thomas Gauler, et al.. (2011). Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Investigational New Drugs. 30(5). 1962–1971.
17.
Fox, Elizabeth, Richard Aplenc, Rochelle Bagatell, et al.. (2010). A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology. 28(35). 5174–5181.
18.
Marotti, Marcelo. (2009). Por que revisar os critérios de resposta em tumores sólidos?. Revista da Associação Médica Brasileira. 55(4). 369–371.
19.
Ming, Eileen E., Michael H. Davidson, Sanjay Gandhi, et al.. (2008). Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. Journal of clinical lipidology. 2(6). 453–463.
20.
Fonseca, Francisco Antônio Helfenstein, Álvaro J. Ruiz, Ernesto Germán Cardona-Muñóz, et al.. (2005). The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Current Medical Research and Opinion. 21(8). 1307–1315.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jolanda Paolini Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Zofia Piotrowska Breakdown of academic impact, for papers by Hiroaki Akamatsu Breakdown of academic impact, for papers by David A. Ramies Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Kathryn H. Brown Breakdown of academic impact, for papers by Viola W. Zhu Breakdown of academic impact, for papers by Bogdana Balas Breakdown of academic impact, for papers by Russell F. DeVore